Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Forty Seven Inc (FTSV_old)

NASDAQ
Currency in USD
Disclaimer
95.51
0.00(0.00%)
Real-time Data
Fair Value
Unlock Value
Day's Range
95.4695.52
52 wk Range
0.0095.52
Prev. Close
95.51
Open
95.46
Day's Range
95.46-95.52
52 wk Range
0-0
Volume
0
Average Volume (3m)
-
1-Year Change
0%
Shares Outstanding
48,156,251
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More
How do you feel today about FTSV_old?
Vote to see community's results!
or

Forty Seven Company Profile

Forty Seven, Inc., a clinical-stage immuno-oncology company, focuses on developing novel therapies to activate macrophages for the treatment of cancer. It offers magrolimab, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. The company has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin’s lymphoma; and collaboration with Acerta Pharma to evaluate novel immuno-oncology triple combination in diffuse large B-Cell Lymphoma. Forty Seven, Inc. was formerly known as CD47 Sciences, Inc. The company was incorporated in 2014 and is headquartered in Foster City, California. It has locations in North America, South America, Asia, the Middle East, Africa, Australia, and Europe. Forty Seven, Inc. operates as a subsidiary of Gilead Sciences, Inc.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.